15 July 2024
Freshfields advises Hasten Biopharmaceuticals on acquisition of Celltrion Healthcare product portfolios
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Alan Wang Lead | Freshfields | Partner | Not stated | Not stated |
| Ya Ma | Freshfields | Counsel | Not stated | Not stated |
| Sunny Min | Freshfields | Associate | Not stated | Not stated |
| Yichen Xing | Freshfields | Associate | Not stated | Not stated |
| David Brooks | Freshfields | Partner | IP matters | Not stated |
| Philipp Dohnke | Freshfields | Partner | IP matters | Not stated |
| Philipp Lehman | Freshfields | Counsel | IP matters | Not stated |
| John Scurr | Freshfields | Counsel | IP matters | Not stated |
| Ben Cohen | Freshfields | Senior associate | IP matters | Not stated |
| Babak Hakimian | Freshfields | Associate | IP matters | Not stated |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Hasten BiopharmaceuticalsBuy-side
- Counterparties
- Celltrion Healthcare (Sell-side)